4D Molecular Therapeutics Inc (FDMT) — Cash Flow Reinvestment Rate
4D Molecular Therapeutics Inc (FDMT) has a Cash Flow Reinvestment Rate of 4.54x as of December 2025, reinvesting $129.55 Million (capex $631.00K plus investments $-128.92 Million) from operating cash flow of $28.55 Million. Explore 4D Molecular Therapeutics Inc capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
4D Molecular Therapeutics Inc Cash Flow Reinvestment Rate (2017–2017)
Historical reinvestment intensity for 4D Molecular Therapeutics Inc across 1 annual periods. Also explore balance sheet size of 4D Molecular Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for 4D Molecular Therapeutics Inc (2017–2017)
Year-by-year capital reinvestment analysis for 4D Molecular Therapeutics Inc. For live market cap and broader valuation context, see FDMT market cap.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2017 | 1.07x | $8.80 Million | $8.24 Million | $573.00K | — |